GEOFFREY NICHOL
CIK 1214505 · Executive Vice President, R&D · last filed 2026-01-28
GEOFFREY NICHOL is an Executive Vice President, R&D who has filed 25 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for TPST, was dated Jan 28, 2026.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
25
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TPST | Director | — | $1.26 | — | $0 | 6 | 2026-01-28 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 2 | 2020-06-23 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Executive Vice President, R&D | 159,676 | $0.18 | $28.4K | $0 | 7 | 2015-12-15 |
| MEDX | Senior Vice President | 0 | $34.49 | $0 | $0 | 9 | 2009-09-01 |
Recent Filings
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-28 | TPST | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | TPST | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | TPST | Grant (A) | — | $0 | EDGAR |
| 2022-06-22 | TPST | Grant (A) | — | $0 | EDGAR |
| 2021-09-20 | TPST | Grant (A) | — | $0 | EDGAR |
| 2021-07-06 | TPST | Grant (A) | — | $0 | EDGAR |
| 2020-06-23 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-12-19 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-12-15 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Tax (F) | −9,081 | -$78.8K | EDGAR |
| 2015-12-09 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | +30,611 | -$66.8K | EDGAR |